• Mashup Score: 31

    Trevor Bedford (@trvrb) Fred Hutchinson Cancer Center / Howard Hughes Medical Institute 23 Aug 2022 From Trees to Public Health Policy Module International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology   Slides at:…

    Tweet Tweets with this article
    • I was invited by @VandammeAm and other organizers of the #VEME2022 Virus Evolution and Molecular Epidemiology Workshop to present my perspective on applying pathogen phylogenetics for decision making. Slides from my talk are available here: https://t.co/dcRz1LSpbP.

  • Mashup Score: 84

    This study estimates the effectiveness of previous infection with SARS-CoV-2 in preventing reinfection with Omicron BA.4/BA.5 subvariants using a test-negative, case–control study design. Cases (SARS-CoV-2-positive test results) and controls (SARS-CoV-2-negative test results) were matched according to sex, 10-year age group, nationality, comorbid condition count, calendar week of testing, method…

    Tweet Tweets with this article
    • Although it's difficult to estimate long-term rate of R→S for SARS-CoV-2, we can extrapolate from @HebAltarawneh et al's finding of 76% effectiveness of BA.1 infection to prevent BA.4/BA.5 reinfection (https://t.co/tPcceilmmk). 9/11

  • Mashup Score: 747

    100,000 annual deaths may be as good as it gets.

    Tweet Tweets with this article
    • 1/ Endemic Covid-19 Looks Pretty Brutal by @dwallacewells for @nytimes https://t.co/BBHULZIxl3 We haven't had an explicit conversation about this👇🏽 Why not? https://t.co/YP8lqVRzvC

    • This level of circulation and severe outcomes (including long COVID in addition to death) combine to make "endemic" COVID-19 a serious ongoing health burden. Here, @dwallacewells describes this viscerally as "looking pretty brutal". 5/5 https://t.co/kmiWWJnH5I

  • Mashup Score: 12

    Background Updated vaccination strategies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern are needed. Interim results of the safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster candidate are presented. Methods In this ongoing, phase 2/3 trial, the 50-μg bivalent vaccine mRNA-1273.214 (25-μg each ancestral Wuhan-Hu-1 and omicron…

    Tweet Tweets with this article
    • The recent @moderna_tx trial results of a bivalent wildtype + BA.1 vaccine (https://t.co/D40XYenwps) are interesting in this regard. This shows geometric mean titer (GMT) against Omicron BA.1 of 1474 with monovalent wildtype booster and 2372 with bivalent BA.1 booster. 6/10 https://t.co/p8QKHwqJHJ

  • Mashup Score: 33

    Scientists had high hopes for a new coronavirus vaccine that combines the existing formulation with one targeting Omicron, but many are not impressed by the results.

    Tweet Tweets with this article
    • Note here that I fully expect further evolution to occur in the coming months, but that this evolution will most likely be on top of BA.4/BA.5 and so this continued evolution shouldn't dissuade vaccine updates (https://t.co/GmBVg88ZHf). 9/10 https://t.co/XpgzSTnmNJ